I think there ought to be a "Bad Advice" stamp for such posts, to alert newbies.

RareBird wrote on Nov 8^th, 2012 at 6:57pm:



My guess is you will be dead from doing this.  Might reconsider o2 therapy.  Good luck!

I would never do this. Sumatriptan is already made three different ways, which allows for three different ways to administer. There is already a nasal spray for your nose, tablets for your stomach, and injections for your skin. They are not meant for "mix and match" and could be highly dangerous if taken the wrong way. Would you drink from the syringe ?

Eroc wrote on Jul 4^th, 2014 at 9:47am:

And we won't know that they died.  They'd just stop posting...

Multimedia File Viewing and Clickable Links are available for Registered Members only!!  You need to or

HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include a
ll the information needed to use
IMITREX safely and effectively. S
ee full prescribing information for
IMITREX.
IMITREX (sumatriptan) Nasal Spray
Initial U.S. Approval: 1992
----------------------------INDICATIONS AND USAGE ---------------------
IMITREX is a serotonin (5-HT
1B/1D
) receptor agonist (triptan) indicated for
acute treatment of migraine with
or without aura in adults. (1)
Limitations of Use:
•
Use only if a clear diagnosis of migraine headache has been established.
(1)
•
Not indicated for the prophylactic th
erapy of migraine attacks. (1)
•
Not indicated for the treatment of cluster headache. (1)
----------------------- DOSAGE AND ADMINISTRATION ----------------
•
Single dose of 5 mg, 10 mg, or 20 mg of nasal spray. (2)
•
A second dose should only be considered if some response to the first
dose was observed. Separate doses by at least 2 hours. (2)
•
Maximum dose in a 24-hour period: 40 mg. (2)
--------------------- DOSAGE FORMS AND STRENGTHS --------------
Nasal spray: 5 mg and 20 mg (3, 16)
-------------------------------
CONTRAINDICATIONS ------------------------
•
History of coronary artery disease
or coronary artery vasospasm (4)
•
Wolff-Parkinson-White syndrome or other cardiac accessory conduction
pathway disorders (4)
•
History of stroke, transient ischemic
attack, or hemiplegic or basilar
migraine (4)
•
Peripheral vascular disease (4)
•
Ischemic bowel disease (4)
•
Uncontrolled hypertension (4)
•
Recent (within 24 hours) use of another 5-HT
1
agonist (e.g., another
triptan) or of an ergotamin
e-containing medication. (4)
•
Concurrent or recent (past 2 weeks) use of monoamine oxidase-A
inhibitor. (4)
•
Hypersensitivity to IMITREX (angioe
dema and anaphylaxis seen). (4)
•
Severe hepatic impairment (4)
----------------------- WARNINGS AND PRECAUTIONS ----------------
•
Myocardial ischemia/infarction and Pr
inzmetal’s angina: Perform cardiac
evaluation in patients with multiple ca
rdiovascular risk factors. (5.1)
•
Arrhythmias: Discontinue IMITREX if occurs. (5.2)
•
Chest/throat/neck/jaw pain, tightness, pr
essure, or heaviness: Generally
not associated with myocardial ischemia; evaluate for coronary artery
disease in patients at high risk. (5.3)
•
Cerebral hemorrhage, subarachnoid he
morrhage, and stroke: Discontinue
IMITREX if occurs. (5.4)
•
Gastrointestinal ischemic reactions
and peripheral vasospastic reactions:
Discontinue IMITREX if occurs. (5.5)
•
Medication overuse headache: Detoxi
fication may be necessary. (5.6)
•
Serotonin syndrome:
Discontinue IMITREX if occurs. (5.7)
•
Seizures: Use with caution in patients
with epilepsy or a lowered seizure
threshold. (5.11)
------------------------------ ADVERSE REACTIONS -----------------------
Most common adverse reactions (
≥
1% and >placebo) were burning sensation,
disorder/discomfort of nasal cavity/sinus
es, throat discomfort, nausea and/or
vomiting, bad/unusual taste, a
nd dizziness/vertigo. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact
GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or
Multimedia File Viewing and Clickable Links are available for Registered Members only!!  You need to or .